22:55 , May 11, 2018 |  BioCentury  |  Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May 8,...
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global biopharma...
16:38 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

Astellas/Vical CMV vaccine ASP0113 fails stem cell transplant trial

Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary and secondary endpoints in the international Phase III HELIOS trial in CMV-seropositive allogeneic stem cell transplant recipients. The company...
20:17 , Jan 22, 2018 |  BC Extra  |  Clinical News

Astellas/Vical CMV vaccine fails stem cell transplant trial

Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary and secondary endpoints in the Phase III HELIOS trial in CMV-seropositive allogeneic stem cell transplant recipients. Vical sank $0.43...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

Cytomegalovirus: Phase II data

Top-line data from a double-blind, international Phase II trial in 150 CMV-seronegative kidney transplant recipients receiving an organ from a CMV-seropositive donor showed that 5 mg intramuscular ASP0113 missed the primary endpoint of reducing the...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Clinical News

HB-101: Phase I started

Hookipa began a double-blind, placebo-controlled, Belgian Phase I trial to evaluate 3 dose levels of intramuscular HB-101 at day 0 and months 1 and 3 in 54 healthy volunteers. Hookipa Biotech AG, Vienna, Austria   Product:...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interferon-stimulated gene 15 (ISG15); interferon induced protein with tetratricopeptide repeats 1 (IFIT1)

Infectious disease INDICATION: Viral infection Patient sample studies suggest inhibiting ISG15 could help treat viral infections. In vitro, stimulation with interferon α (IFNα) and IFNβ of fibroblasts from ISG15-deficient volunteers induced more persistent expression of the antiviral...
08:00 , Dec 3, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Co-crystal structure of human cytomegalovirus (CMV) glycoprotein B and a broadly neutralizing antibody (bNAb) against CMV to aid vaccine design

Drug platforms TECHNOLOGY: Structural analysesVical Inc.Astellas Pharma Inc.ASP0113SanofiCMV gB/MF59GlaxoSmithKline plcGSK1492903human cytomegalovirus (CMV) glycoprotein B...
07:00 , Jul 30, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Human cytomegalovirus (CMV) type 2 membrane protein (UL50); CMV type 3 membrane protein (UL53)

Infectious disease INDICATION: Cytomegalovirus (CMV) In vitro studies suggest disrupting UL50-UL53 binding could help treat CMV infection. Mutagenesis of UL50 followed by an in vitro UL50-UL53 binding assay identified three mutant forms of the protein, each containing...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Company News

Humabs BioMed, Novartis deal

Humabs received an undisclosed milestone payment from Novartis under a 2009 deal granting the pharma exclusive rights to use mAbs discovered using Humabs Cellclone platform. The milestone was triggered by the start of U.S. and...